Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Pediatric Patients Hospitalized With COVID-19
NCT05074420Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-Time Curve of Baricitinib at Day 4 and Maximum Concentration of Baricitinib at Day 4. Started Dec 2021; status: terminated.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05074420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074420.